MedTrace Logo

Food Supplement for the Treatment of Patients With Amyotrophic Lateral Sclerosis

NCT02588807 · Status: WITHDRAWN · Phase: PHASE1 · Type: INTERVENTIONAL

Last updated 2022-08-09

No results posted yet for this study

Summary

The purpose of the study is to evaluate the safety of combining phospholipids with medicinal plants for treatment of patients with amyotrophic lateral sclerosis (ALS)

Conditions

Interventions

DRUG

Spirit1

Spirit 1 is a combination of phospholipids and anti-oxidant medicinal plants

Sponsors & Collaborators

  • Carmel Medical Center

    collaborator OTHER

  • Herb Spirit

    lead INDUSTRY

Principal Investigators

  • Jacob Meer, MD · Carmel Medical Center

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-01-01
Primary Completion
2021-09-30
Completion
2022-05-31

Countries

  • Israel

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02588807 on ClinicalTrials.gov